Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.
Hersh
Bonnie P
BP
Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA. bonnie_hersh@vmed.org
Earl
Nancy L
NL
Hauser
Robert A
RA
Stacy
Mark
M
D000368:Aged; D003692:Delayed-Action Preparations; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D009069:Movement Disorders / Q000175:diagnosis / Q000453:epidemiology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole